Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elevai Labs, Inc. - Common Stock (NQ: ELAB )

0.6601 +0.0001 (+0.02%)
Streaming Delayed Price Updated: 3:11 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elevai Labs, Inc. - Common Stock

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers 
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
Utility Patent Covers the formulation for ELEVAI’s flagship exosome-based skin care products 
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost 
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
Company Records Record Quarterly Revenues 
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI Labs, Inc. Expands International Distribution into Europe
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
From Elevai Labs Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.